Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview.
The National Kidney Foundation developed and oversees the Kidney Disease Outcomes Quality Initiative, a process that develops clinical practice guidelines in nephrology. Recent guidelines address the aberrations in bone metabolism and disease that occur as a complication of chronic kidney disease. These guidelines provide, for the first time, a standard approach to the detection and management of alterations in calcium, phosphorus, and parathyroid hormone metabolism. The problems and sequelae of soft-tissue calcification are discussed, and recommendations are provided for reducing the associated morbidity and mortality.
Bailie
George R
GR
Albany Nephrology Pharmacy (ANephRx) Group, Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208, USA. bailieg@acp.edu
Massry
Shaul G
SG
D000535:Aluminum / Q000378:metabolism; D001851:Bone Diseases, Metabolic / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy*; D001842:Bone and Bones / Q000378:metabolism; D002114:Calcinosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D002117:Calcitriol / Q000096:biosynthesis; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology; D006962:Hyperparathyroidism, Secondary / Q000209:etiology; D006996:Hypocalcemia / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy*; D008903:Minerals / Q000378:metabolism; D017410:Practice Guidelines as Topic; D014808:Vitamin D Deficiency / Q000209:etiology / Q000517:prevention & control
D008903:Minerals; D000535:Aluminum; D002117:Calcitriol